Traws Pharma (NASDAQ:TRAW) Given “Neutral” Rating at HC Wainwright

Traws Pharma (NASDAQ:TRAW)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $1.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 85.19% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings downgraded Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Citigroup cut Traws Pharma to a “neutral” rating in a report on Monday, June 15th. LADENBURG THALM/SH SH downgraded Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Finally, Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Traws Pharma presently has a consensus rating of “Reduce” and a consensus target price of $1.00.

Traws Pharma Price Performance

Shares of NASDAQ:TRAW opened at $0.54 on Tuesday. Traws Pharma has a one year low of $0.43 and a one year high of $3.27. The company has a market cap of $8.18 million, a price-to-earnings ratio of -0.31 and a beta of 1.57. The firm has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $1.35.

Traws Pharma (NASDAQ:TRAW) last posted its earnings results on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. As a group, analysts expect that Traws Pharma will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TRAW. Two Sigma Investments LP grew its position in shares of Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after buying an additional 5,955 shares during the last quarter. State Street Corp acquired a new stake in shares of Traws Pharma in the fourth quarter valued at about $29,000. XTX Topco Ltd raised its position in shares of Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after acquiring an additional 31,502 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Traws Pharma during the fourth quarter worth about $56,000. Finally, Geode Capital Management LLC lifted its stake in shares of Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after acquiring an additional 18,213 shares during the period. 7.95% of the stock is owned by institutional investors.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.